Clinical trial
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With…
NCT00299182 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00299182 |
|---|---|
| Title | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma |
| Official title | Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo |
| Enrollment | 50 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2012 |
| First posted | Mar 6, 2006 |
| Last update posted | Sep 21, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: